IDH2 and central nervous system cancer: The IDH mutation has recently gained clinical importance as a therapeutic target since vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, significantly improved progression-free survival in patients with CNS WHO grade 2 IDH-mutant gliomas [32].